CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 199 filers reported holding CLOVIS ONCOLOGY INC in Q3 2015. The put-call ratio across all filers is 0.94 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $121,000 | -33.9% | 101,855 | 0.0% | 0.21% | -26.7% |
Q2 2022 | $183,000 | -11.2% | 101,855 | 0.0% | 0.28% | +36.4% |
Q1 2022 | $206,000 | -25.4% | 101,855 | 0.0% | 0.21% | +39.2% |
Q4 2021 | $276,000 | -39.2% | 101,855 | 0.0% | 0.15% | -21.3% |
Q3 2021 | $454,000 | -23.2% | 101,855 | 0.0% | 0.19% | -4.1% |
Q2 2021 | $591,000 | -17.3% | 101,855 | 0.0% | 0.20% | +41.0% |
Q1 2021 | $715,000 | +46.2% | 101,855 | 0.0% | 0.14% | +172.5% |
Q4 2020 | $489,000 | -17.7% | 101,855 | 0.0% | 0.05% | -53.2% |
Q3 2020 | $594,000 | -99.9% | 101,855 | 0.0% | 0.11% | +10.1% |
Q2 2020 | $687,521,000 | +6.1% | 101,855 | 0.0% | 0.10% | -44.4% |
Q1 2020 | $647,798,000 | -39.0% | 101,855 | 0.0% | 0.18% | -44.4% |
Q4 2019 | $1,061,838,000 | +165.3% | 101,855 | 0.0% | 0.32% | +106.5% |
Q3 2019 | $400,290,000 | -73.6% | 101,855 | 0.0% | 0.16% | -64.9% |
Q2 2019 | $1,514,584,000 | -40.1% | 101,855 | 0.0% | 0.44% | -47.1% |
Q1 2019 | $2,528,041,000 | +38.2% | 101,855 | 0.0% | 0.83% | -8.1% |
Q4 2018 | $1,829,316,000 | -38.8% | 101,855 | 0.0% | 0.91% | -10.9% |
Q3 2018 | $2,991,481,000 | -35.4% | 101,855 | 0.0% | 1.02% | -29.6% |
Q2 2018 | $4,631,347,000 | -13.9% | 101,855 | 0.0% | 1.44% | -16.0% |
Q1 2018 | $5,377,944,000 | -22.4% | 101,855 | 0.0% | 1.72% | -76.4% |
Q4 2017 | $6,926,140,000 | -17.4% | 101,855 | 0.0% | 7.29% | +14.2% |
Q3 2017 | $8,384,704,000 | -12.1% | 101,855 | 0.0% | 6.38% | -15.0% |
Q2 2017 | $9,542,795,000 | -63.2% | 101,855 | -75.0% | 7.51% | -60.2% |
Q1 2017 | $25,940,177,000 | +43.3% | 407,416 | 0.0% | 18.86% | +7.1% |
Q4 2016 | $18,097,419,000 | +23.2% | 407,416 | 0.0% | 17.62% | +7.6% |
Q3 2016 | $14,687,347,000 | +162.8% | 407,416 | 0.0% | 16.38% | +189.1% |
Q2 2016 | $5,589,748,000 | -28.5% | 407,416 | 0.0% | 5.66% | +0.3% |
Q1 2016 | $7,822,387,000 | -45.1% | 407,416 | 0.0% | 5.65% | -32.3% |
Q4 2015 | $14,259,560,000 | -61.9% | 407,416 | 0.0% | 8.34% | -61.2% |
Q3 2015 | $37,465,975,000 | +4.6% | 407,416 | 0.0% | 21.49% | -52.7% |
Q2 2015 | $35,803,718,000 | -40.8% | 407,416 | -50.0% | 45.41% | -14.6% |
Q1 2015 | $60,485,054,000 | +32.6% | 814,833 | 0.0% | 53.20% | +21.9% |
Q4 2014 | $45,630,648,000 | – | 814,833 | – | 43.63% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |